Thomas Seidl, PhD

Thomas Seidl, PhD : Chief Executive Officer, Chief Science Officer, Member of the Board, President and Treasurer

Thomas assumed the role of CEO of the Company in November 2020. He brings extensive experience in management, research, development, and clinical validation for breakthrough diabetes technologies. Prior to being CEO, Thomas led the development of the hollow glucose sensor as Chief Science Officer, starting in 2017. As CSO, Thomas led the optimization of the chemistry and coating process, the hollow sensor design and the fabrication process development. Prior to joining the Company, Thomas was Manager of Polymer Development at Bayer HealthCare, Diabetes Care. Thomas holds a BS (2000) in Chemistry and an MS in Cell and Molecular Biology (2002) from the University of Hawaii at Manoa. He earned his doctorate in Synthetic Organic Chemistry from Portland State University in 2017.